Overview

Double Blind Study on the Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids.

Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
A Randomized Phase 2 double blind study which aims to determine the safety and efficacy of CITI-002 cream in adult patients with Goligher's grade II or III hemorrhoids.
Phase:
Phase 2
Details
Lead Sponsor:
Citius Pharmaceuticals, Inc.
Collaborator:
Therapeutics, Inc.
Treatments:
Clobetasol
Halobetasol
Lidocaine